Enemem, >>> I think it is quite possible that they are well along on a more comprehensive deal that needed the RD piece to get resolved before being closed. I think that a deal in the near term may obviate the need to raise funds. <<<
That would be nice, but when it comes to Cortex, I can't remember something good like that ever happening. Everything takes forever, multiplied by two or three.
The obvious thing to partner off are the respiratory indications, which will give Cortex the funds to advance ADHD in-house. Problem is, the Biovail negotiations took so long because they (Biovail) were apparently the only seriously interested party. As Neuro mentioned, Biovail was something of an oddity, a CNS company still moving ahead into riskier/new CNS areas. Finding another Biovail may not be easy in the new risk averse CNS world.
And RD itself is an oddball/niche area that won't appeal to many companies. I'd be surprised if they can get RD partnered again before the end of 2011.
News 
Market Data 
Discover 
AI
